Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »

Libby's H*O*P*E* › Comments

Libby's H*O*P*E*
2014 AACR: Immunovaccine to Present Data on Cancer Vaccine Combination Therapies at the 2014 AACR Annual Meeting - MarketWatch - http://www.marketwatch.com/story...
Combining with cyclophosphamide and the checkpoint inhibitor anti-PD-1 enhances the therapeutic potential of vaccine. - Libby's H*O*P*E*
Libby's H*O*P*E*
Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. [Mol Clin Oncol. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Therefore, we considered it justified to classify patients with clear cell/mucinous adenocarcinoma who relapsed within 12 months as platinum-resistant and those who relapsed after 12 months as platinum-sensitive. - Libby's H*O*P*E*
Libby's H*O*P*E*
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression... [Int J Gynecol Cancer. 2014] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Dasatinib in combination with relapse chemotherapeutic agents seems to interact in a synergistic or additive manner in cells with high SRC pathway activation and protein expression. - Libby's H*O*P*E*
Libby's H*O*P*E*
Epigenetic determinants of ovarian clear cell carcinoma biology.... [Int J Cancer. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Preclinical study results suggest that decitabine may be effective against ovarian clear cell cancer. - Libby's H*O*P*E*
Libby's H*O*P*E*
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.... [Invest New Drugs. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Eight patients achieved stable disease (SD) ≥ 6 months (six platinum failures) and one patient with platinum-resistant ovarian cancer, partial response (PR) (total SD ≥ 6 months/PR = 9, 16.4 %). - Libby's H*O*P*E*
Libby's H*O*P*E*
2013 AACR-NCI-EORTC Mtg: Verastem's Results Support Continued Development of VS-6063 (defactinib)(FAK inhibitor) Across Multiple Tumor Types, including Ovarian .....http://www.businesswire.com/news...
Results from the Phase 1 dose escalation portion of the study were presented. Six patients with advanced or refractory ovarian cancer, all of whom had prior taxane exposure and were platinum resistant, were enrolled. Two patients demonstrated significant decreases, or normalization, of CA-125, a marker that becomes elevated with disease progression in ovarian cancer. One patient in the VS-6063 200mg BID cohort experienced an ongoing complete response as confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) with repeated radiologic scans and a second patient in the VS-6063 400mg BID cohort continues to experience prolonged stabilization of her disease. Patient recruitment remains ongoing in the expansion Phase 1b open-label, multicenter portion of the study, where Verastem expects to enroll a total of approximately 15 patients at three U.S. locations. - Libby's H*O*P*E*
Libby's H*O*P*E*
Data From Phase I Clinical Trial Of Mitochondrial Inhibitor Drug ME-344 Reveals 35% Disease Control Rate in Refractory Solid Tumors - http://investor.meipharma.com/2013-10...
As reported in the abstract of the presentation, eight of the 23 patients evaluable for efficacy (35%) achieved disease control, including one confirmed partial response (PR) in a patient with refractory small cell lung cancer (duration 52+ weeks) and seven patients with prolonged stable disease (SD) ranging from 8 to 40+ weeks. The maximum tolerated dose was established at 10 mg kg delivered on a weekly schedule. Dose limiting toxicity of Grade 3 neuropathy was observed at 15 mg/kg and 20 mg/kg. Based on these findings, MEI Pharma is actively preparing for a phase Ib clinical trial of ME-344 in combination with Hycamtin (topotecan) in small cell lung cancer and ovarian cancer, which it expects to initiate during the second quarter of 2014.” - Libby's H*O*P*E*
Libby's H*O*P*E*
Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer - http://www.sciencedirect.com/science...
Platinum-taxane chemotherapy remains the standard of care for the primary treatment of optimally cytoreduced advanced epithelial ovarian cancer. Primary intraperitoneal cisplatin-based chemotherapy has been shown to improve survival in the setting of optimal residual advanced ovarian cancer. The role of bevacizumab in the primary anti-neoplastic drug management of optimal residual advanced ovarian cancer remains to be defined. - Libby's H*O*P*E*
Libby's H*O*P*E*
Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer - http://www.sciencedirect.com/science...
Feasibility of a novel treatment approach involving local IL-12 gene therapy and IV standard chemotherapy for ovarian cancer is described. he combination treatment was safe and associated with anticancer efficacy and IL-12 biological activity. Addition of local IL-12 gene therapy to standard chemotherapy offers a novel approach to the treatment of advanced cancers - Libby's H*O*P*E*
Libby's H*O*P*E*
Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: A single institution experience from 1999 to 2010 - http://www.sciencedirect.com/science...
58% of patients with gynecologic cancer achieved clinical benefit, and 9.2% experienced DLT in phase 1 trials. - Libby's H*O*P*E*
Libby's H*O*P*E*
Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility - http://www.sciencedirect.com/science...
NCCN compliant treatment and survival are reportedly improved at high volume hospitals, arguing for centralization of care. The low volume hospital achieved 85% NCCN treatment compliance, 73% optimal surgical cytoreduction, and 37 month overall survival rates. Hospital volume alone is not a reliable metric for quality patient care. - Libby's H*O*P*E*
Libby's H*O*P*E*
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer - http://www.sciencedirect.com/science...
Study on the association between c-Abl overexpression and metastasis of EOC is rare. Up-regulated c-Abl expression is associated with an unfavorable prognosis and is an independent prognostic factor for EOC. c-Abl may be a potential effective prognostic marker for EOC. - Libby's H*O*P*E*
Libby's H*O*P*E*
Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors - http://www.sciencedirect.com/science...
Granulosa cell tumors are almost exclusively complex and are most frequently greater than 10 cm. There was a near equal distribution of granulosa cell tumors with a CA125 greater than or less than 35. If complexity and a CA125 level > 35 are used to predict GCTs, we will frequently fail to predict them. - Libby's H*O*P*E*
Libby's H*O*P*E*
Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer - http://www.sciencedirect.com/science...
With HE4 and CA125 we can diagnose the aggressive type II EOC at all stages and ages most correctly. The diagnostic safety for the dual markers HE4 and CA125 is not acceptable in early stage type I EOC. Our results support that EOC should be looked upon as several different diseases. - Libby's H*O*P*E*
Libby's H*O*P*E*
Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome - http://www.sciencedirect.com/science...
Ovarian carcinosarcomas are aggressive tumors with a natural history that is distinct from serous cancers. The survival for both early and late stage carcinosarcoma is inferior to serous tumors. - Libby's H*O*P*E*
Libby's H*O*P*E*
Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors - http://www.sciencedirect.com/science...
The anatomic site of relapse is a strong predictor of post-relapse survival in patients with localized recurrent ovarian cancer. Secondary cytoreductive surgery ensures a relevant survival benefit in women with localized recurrent ovarian cancer. - Libby's H*O*P*E*
Libby's H*O*P*E*
Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: Is there a case for thoracic cytoreduction? - http://www.sciencedirect.com/science...
Study reported 68% optimal cytoreduction in stage IV (all sites) as compared to 83.5% in stage IIIc. Sites of recurrence were rarely thorax alone (6.8%). Thoracic debulking is likely to change the course of disease in few individual patients only. - Libby's H*O*P*E*
Libby's H*O*P*E*
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma — Analysis of patient data in the prospective OVCAD study - http://www.sciencedirect.com/science...
The study findings suggest that delayed initiation of chemotherapy might compromise overall survival in patients with advanced serous ovarian cancer, especially when suboptimally debulked. - Libby's H*O*P*E*
Libby's H*O*P*E*
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas - http://www.sciencedirect.com/science...
ABCB1 C1236T (rs1128503) was marginally associated with improved overall survival in 4,616 invasive ovarian cancer patients regardless of chemotherapy. Analysis of an additional 1,562 SNPs flanking ABCB1 in ~ 3000 invasive ovarian cancer patients yielded no new signals. Analysis of ABCB1 expression in 143 ovarian tumors showed that ABCB1 expression may worsen prognosis in sub-optimally debulked patients. - Libby's H*O*P*E*
Libby's H*O*P*E*
Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients - http://www.sciencedirect.com/science...
Number and severity of life stressors were unrelated to participants' QOL before surgery. Greater number of life stressors at one-year post surgery was related to poorer concurrent quality of life. Greater number of life stressors prior to surgery predicted poorer overall QOL at one year. - Libby's H*O*P*E*
Libby's H*O*P*E*
Clinical Risk Factors of PEGylated Liposomal Doxorubicin (Doxil) Induced Palmar Plantar Erythrodysesthesia in Recurrent Ovarian Cancer Patients - http://www.sciencedirect.com/science...
Nearly 25% of recurrent ovarian cancer patients treated with PEGylated liposomal doxorubicin developed palmar plantar erythrodysesthesia (PPE). Body mass index may be associated with PPE. PPE occurred early in treatment and was not associated with time to progression. - Libby's H*O*P*E*
Libby's H*O*P*E*
Bevacizumab (Avastin) + Pemetrexed (Alimta) found active against recurrent or persistent ovarian cancer in phase II study. - http://www.sciencedirect.com/science...
This phase II study of bevacizumab/pemetrexed in recurrent ovarian cancer showed a response rate of 41%. Median overall survival was 16.7 months for platinum-resistant and 26.5 months for platinum-sensitive patients. Two cases of therapy-related myeloid neoplasms were noted as a potential new toxicity. - Libby's H*O*P*E*
Libby's H*O*P*E*
BMN 673 monotherapy (PARP 1/2 inhibitor) makes splash in BRCA-mutated ovarian, breast cancer : OBGYN News - http://www.obgynnews.com/single-...
Among 25 ovarian cancer patients evaluable by RECIST, 1 patient had a complete response, 10 had partial responses, and 4 had stable disease lasting 24 weeks or more, Dr. Ramanathan reported. Responses were seen in 17 of 22 platinum-sensitive patients. "Platinum sensitivity may be important in identifying patients sensitive to BMN 673," he said. Cancer antigen 125 levels evaluable in 27 ovarian cancer patients dropped by more than 50% in 19 (70%) and returned to the normal range in 9. - Libby's H*O*P*E*
Libby's H*O*P*E*
Ongoing Phase I monotherapy study of rucaparib (PARP 1/2 inhibitor) in patients with solid tumors with solid tumors demonstrates clinical activity - http://phx.corporate-ir.net/phoenix...
Overall, 100% (11/11) of ovarian cancer patients with inherited BRCA mutations achieved disease control as defined by CR, PR, or stable disease (SD)>12 weeks and 63% (5/8) have achieved disease control as defined by CR, PR, or SD >24 weeks – the three patients who progressed by week 24 were all treated in dose cohorts of 300 mg QD or lower. - Libby's H*O*P*E*
Libby's H*O*P*E*
PharmaMar Announces Top line Results for PM01183 Phase II trial in Patients with Platinum Resistant/Refractory Ovarian Cancer | Small Molecules | News Channels -...
30.3% of patients with platinum resistant disease responded to treatment with PM01183, while no patients in the topotecan arm responded; 82% of patients with platinum resistant disease treated with PM01183 compared to 50% of patients treated with topotecan exhibited a clinical benefit. The median progression-free survival (PFS) in resistant disease was 4.8 months for PM01183 and 1.7 months for topotecan (p=0.0004). Although survival data is not yet mature, a significant increase in overall survival was observed in patients treated with PM01183 compared to topotecan - Libby's H*O*P*E*
Libby's H*O*P*E*
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.... [Ann Surg Oncol. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
In this largest known database for secondary cytoreductive surgery, residual tumor retains its high impact on survival even in the tertiary setting of ovarian cancer. In specialized centers high rates of complete tumor resection can be obtained. Prospective analyses are warranted to define the value of secondary cytoreductive surgery in epithelial ovarian cancer. - Libby's H*O*P*E*
Libby's H*O*P*E*
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1 amplified ovarian cancer.... [Clin Cancer Res. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
These findings suggest that CyclinE1/CDK2 is an important therapeutic target in HGSC, but that resistance to CDK2 inhibitors may emerge due to upregulation of CDK2 target protein and pre-existing cellular polyploidy. - Libby's H*O*P*E*
Libby's H*O*P*E*
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial : The Lancet Oncology -...
For the long-term analysis, median follow-up was 76.8 months. Data indicated that median progression-free survival (PFS) was significantly longer among patients assigned to the dose-dense regimen (28.2 months vs. 17.5 months; HR=0.76; 95% CI, 0.62-0.91). Women assigned to the dose-dense regimen also experienced significantly longer overall survival (OS) (100.5 months vs. 62.2 months; HR=0.79; 95% CI, 0.63-0.99). Result did not apply to clear cell and mucinous epithelial ovarian cancer subtypes. - Libby's H*O*P*E*
Libby's H*O*P*E*
HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.... [Int J Cancer. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
these data show that the HSP27 is required for the pro-invasive and pro-metastatic activity of HGF and suggest that HSP27 might be not only a marker of progression of ovarian cancer, but also a suitable target for therapy. - Libby's H*O*P*E*
Libby's H*O*P*E*
Ubiquitin E3 Ligase CRL4CDT2/DCAF2 as a Potential Chemotherapeutic Target for Ovarian Surface Epithelial Cancer.... [J Biol Chem. 2013] - PubMed - NCBI - http://www.ncbi.nlm.nih.gov/pubmed...
Taken together, these results indicate that CRL4CDT2 is a potential drug target in ovarian cancers and that MLN4924 may be an effective anticancer agent for targeted ovarian cancer therapy. - Libby's H*O*P*E*
Other ways to read this feed:Feed readerFacebook